Dr Reddys names new CFO
Mr Vohra was the deputy CFO and his elevation has been part of the company’s leadership development and transition program. Mr Vohra joined Dr Reddy’s in 2002 from
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
Utilizing King’s proprietary technology, Embeda capsules contain extended-release morphine pellets, each with a sequestered core of naltrexone, an opioid antagonist. The formulation is designed to work such that